PL4000615T3 - Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek - Google Patents
Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerekInfo
- Publication number
- PL4000615T3 PL4000615T3 PL20207534.7T PL20207534T PL4000615T3 PL 4000615 T3 PL4000615 T3 PL 4000615T3 PL 20207534 T PL20207534 T PL 20207534T PL 4000615 T3 PL4000615 T3 PL 4000615T3
- Authority
- PL
- Poland
- Prior art keywords
- dual
- renal diseases
- tnfr2 agonists
- tnfr1 antagonists
- tnfr1
- Prior art date
Links
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 title 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207534.7A EP4000615B1 (en) | 2020-11-13 | 2020-11-13 | Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4000615T3 true PL4000615T3 (pl) | 2022-12-19 |
Family
ID=73448924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20207534.7T PL4000615T3 (pl) | 2020-11-13 | 2020-11-13 | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12083097B2 (pl) |
| EP (1) | EP4000615B1 (pl) |
| JP (1) | JP7462116B2 (pl) |
| CN (1) | CN116568296A (pl) |
| AU (1) | AU2021378077B2 (pl) |
| CA (1) | CA3197986A1 (pl) |
| ES (1) | ES2930093T3 (pl) |
| PL (1) | PL4000615T3 (pl) |
| WO (1) | WO2022101389A1 (pl) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110178112A1 (en) * | 2006-01-18 | 2011-07-21 | Evolva Sa | PPAR Modulators |
| WO2008089462A2 (en) * | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| CA2676444C (en) * | 2007-01-18 | 2013-07-30 | Evolva Sa | Prodrugs of substituted 1,3-dioxanes and their uses |
| US20160193179A1 (en) * | 2012-12-18 | 2016-07-07 | Kjell Steinar Sakariassen | Treatment of Cardiovascular Risk in Diabetic Patients |
| WO2015193630A1 (en) * | 2014-06-18 | 2015-12-23 | Evolva Sa | Treatment of cardiovascular risk in patients with cardiovascular disease and/or diabetes |
| CN111825547B (zh) * | 2019-04-23 | 2022-04-19 | 南京海融医药科技股份有限公司 | 一种芳基丙酸类化合物的盐及其制药用途 |
-
2020
- 2020-11-13 PL PL20207534.7T patent/PL4000615T3/pl unknown
- 2020-11-13 EP EP20207534.7A patent/EP4000615B1/en active Active
- 2020-11-13 ES ES20207534T patent/ES2930093T3/es active Active
-
2021
- 2021-11-12 CN CN202180074898.5A patent/CN116568296A/zh active Pending
- 2021-11-12 US US18/252,339 patent/US12083097B2/en active Active
- 2021-11-12 CA CA3197986A patent/CA3197986A1/en active Pending
- 2021-11-12 JP JP2023528450A patent/JP7462116B2/ja active Active
- 2021-11-12 AU AU2021378077A patent/AU2021378077B2/en active Active
- 2021-11-12 WO PCT/EP2021/081482 patent/WO2022101389A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022101389A1 (en) | 2022-05-19 |
| CN116568296A (zh) | 2023-08-08 |
| ES2930093T3 (es) | 2022-12-07 |
| AU2021378077B2 (en) | 2024-03-14 |
| EP4000615A1 (en) | 2022-05-25 |
| EP4000615B1 (en) | 2022-10-19 |
| AU2021378077A1 (en) | 2023-05-25 |
| JP7462116B2 (ja) | 2024-04-04 |
| US12083097B2 (en) | 2024-09-10 |
| US20230414562A1 (en) | 2023-12-28 |
| CA3197986A1 (en) | 2022-05-19 |
| JP2023554588A (ja) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3806955T1 (sl) | Agonisti receptorja glp-1 in njihova uporaba | |
| IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. | |
| IL274836A (en) | Dosing plan of vidofludimus for use in the prevention or treatment of chronic inflammatory diseases and/or autoimmune diseases | |
| PL4025592T3 (pl) | Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej | |
| PL3806898T3 (pl) | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu | |
| PL3993876T3 (pl) | Przeciwciała anty-cd154 i ich zastosowania | |
| IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
| PT4082570T (pt) | Anticorpo anti-ctla-4 e a sua utilização | |
| HUE070907T2 (hu) | Gonadotropin-felszabadító hormon antagonistát tartalmazó adagolási rend méhfibrómák kezelésére és menstruációs vérveszteség csökkentésére | |
| EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| IL277634A (en) | Leptin receptor agonist antibody for use in the treatment of metabolic dysfunction or hypoleptinemia | |
| IL278207A (en) | Use of neutrophil elastase inhibitors in liver disease | |
| EP4043026A4 (en) | GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
| CL2016000788A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. (divisional de la solicitud 27-2016) | |
| PL3970344T3 (pl) | Zarządzanie buforem w systemach dostarczania zawartości | |
| EP4054597A4 (en) | BLOOD PLASMA FRACTIONS FOR USE IN MUSCLE REGENERATION | |
| HRP20260115T1 (hr) | Agonisti crf2 receptora i njihova primjena u terapiji | |
| IL325810A (en) | Deoxycytidine for use in cancer treatments | |
| IL291661A (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| EP2548893A4 (en) | DOUBLE ANTAGONIST FOR TNF-ALPHA AND IL-21 FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES | |
| PL2948156T3 (pl) | Zastosowanie soli wolframu (vi) w leczeniu niepłodności żeńskiej u nie chorujących na cukrzycę ssaków |